$5.94
0.67% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Abeona Therapeutics, Inc. Stock price

$5.94
-0.56 8.62% 1M
+1.88 46.31% 6M
+0.93 18.56% YTD
+1.13 23.49% 1Y
-12.99 68.61% 3Y
-65.81 91.72% 5Y
+2.41 68.03% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.04 0.67%
ISIN
US00289Y1073
Symbol
ABEO
Sector
Industry

Key metrics

Market capitalization $258.22m
Enterprise Value $171.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.63
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.75m
Free Cash Flow (TTM) Free Cash Flow $-50.72m
Cash position $110.04m
EPS (TTM) EPS $-2.70
P/E forward negative
P/S forward 2,582.20
EV/Sales forward 1,712.90
Short interest 6.29%
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Abeona Therapeutics, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
100%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.83 3.83
10% 10%
-
-3.83 -3.83
4,888% 4,888%
-
- Selling and Administrative Expenses 20 20
50% 50%
-
- Research and Development Expense 33 33
9% 9%
-
-57 -57
31% 31%
-
- Depreciation and Amortization 3.83 3.83
10% 10%
-
EBIT (Operating Income) EBIT -61 -61
29% 29%
-
Net Profit -71 -71
83% 83%
-

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
12 days ago
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025
Neutral
GlobeNewsWire
14 days ago
CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona's resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermoly...
Neutral
GlobeNewsWire
22 days ago
CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024:
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 84
Founded 1974
Website www.abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today